Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.


NDAQ:GILD - Post by User

Bullboard Posts
Post by logicaltruth1on Apr 04, 2015 1:34pm
177 Views
Post# 23597012

Can anyone explain the $234 value on this $98 stock?

Can anyone explain the $234 value on this $98 stock?
Sorry folks. Complete novice here (although I've been trading for years non consistently).  One tool I use (VST) rates this GILD stock at $234 so it came up on my "value" search?  In reseaching this stock is not a small cap, it's in a hot area, etc, why is the stock trading so cheap in relation to value?  I'm sure if I look back I'll see why but what about the future?  VST still rates this stock as HOLD but i think it's a BUY.  Seems it was impacted late last year (year end loss selling or impatient biotech expectations?)   The last buy rating from VST was March 20th 2015 at 102. and last SELL rating was Dec 24th 2014...  I don't always undertstand the recommendations on this thing but I do *try* to understand value... :-)  I could see why people could get really impatient holding this stock while it seems to flutter in the wind...
Bullboard Posts